Zeel® has been researched for over 40 years and has been used extensively by patients in approximately 20 countries. Each year, hundreds of thousands of patients are treated with Zeel® to treat degenerative joint disease. Zeel® is produced in Germany by Biologische Heilmittel Heel GmbH and distributed in 20 countries worldwide.
In Greece, Zeel® was granted a marketing authorization as an OTC medicine and is available in pharmacies from the company A.S.K. Pharmaceutical in two easy-to-use formulations: tablet and cream. Zeel® tablet1 is used to relieve the symptoms of pain and inflammation of the joint damage associated with arthropathy. Zeel® cream2 is used topically for the symptomatic treatment of arthropathy pain.
Each individually inhibit both LOX-5 and COX (COX-1 and COX-2)
Inhibits COX (COX-1 and COX-2), inhibits prostaglandin biosynthesis and PAF induced exocytosis.
Suppresses the proliferative effect of VEGF on endothelial cell line, probably mediated by blocking the VEGF-induced Akt activation.
Reporting of suspected adverse reactions.
Healthcare professionals are asked to report any suspected adverse reactions via the National Organization of Medicines. If you are a patient and you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in the package leaflet. You can report adverse reactions with the following options:
1) Electronic submission through EOF’s website http://www.eof.gr/web/guest/yellowgeneral
2) Dispatching the Yellow card in hard copy via mail to EOF to the Department of Adverse Reactions (Mesogeion 284, Cholargos 15562)
3) Communication with the Department of Adverse Reactions via telephone: 18.104.22.1680-337
4) Submission of the yellow card via fax at 210.6549.585